Table 2.
Trends of SLE features across vaccinations.
| Before Vaccination | After Vaccination | End of Follow-Up | |
|---|---|---|---|
| Disease status | |||
| Patients in LLDAS: n (%) | 9 (82) | 8 (80) | 8 (80) |
| SLEDAI-2K: median (IQR) | 2 (0–3) | 2 (0–4) | 1 (0–2) |
| BILAG constitutional: median (IQR) | 0 (0–0) | 0 (0–1) * | 0 (0–0) |
| BILAG mucocutaneous: median (IQR) | 0 (0–1) | 0 (0–1) | 0 (0–0) |
| BILAG musculoskeletal: median (IQR) | 0 (0–0) | 0 (0–1) | 0 (0–0) |
| BILAG haematological: median (IQR) | 0 (0–1) | 1 (0–1) | 1 (0–1) |
| BILAG neuropsychiatric: median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| BILAG cardiorespiratory: median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| BILAG gastrointestinal: median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| BILAG ophthalmic: median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| BILAG renal: median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| SLICC/ACR damage index: median (IQR) | 1 (1–3) | 2 (1–3) | 2 (1–3) |
| PDN dose (mg/day): median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
* p < 0.05 compared to the pre-vaccination status by ranked sign test.